Surbiton, UK - Medical polymer and device developer AorTech International plc has received an Australian Patent for its biostable polyurethane Elast-Eon 5 (E5). The patent expands AorTech's portfolio of biostable materials to include softer ranges, said a 21 August statement from Aortech.
"This new material retains the superior biostability and mechanical properties for which Elast-Eon is known," claims the company, which has development operations in Australia.
The patent is entering the national phase in other countries including the US and the European Union, with patents expected in these regions in 2009.
According to an article published in the Journal of Biomedical Materials Research in January 2008, silicone-based Elast-Eons are "significantly superior to all other medical polyurethanes with respect to long term biostability," said Aortech's statement.
And the soft, more flexible grades, increase "market opportunities for Elast-Eon into medical device groups that have historically been manufactured from silicone materials," said Ajay Padsalgikar, AorTech chief scientific officer. "E5's softer properties and superior flexibility "Designers of these devices can now utilise a softer material with superior mechanical properties," he added.